Collegium Pharmaceutical Inc buy tamam
Start price
21.06.18
/
50%
€24.70
Target price
03.06.19
€36.08
Performance (%)
-57.85%
End price
03.06.19
€10.41
Summary
This prediction ended on 03.06.19 with a price of €10.41. Massive losses of -57.85% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Collegium Pharmaceutical Inc | -0.699% | -0.699% | 5.185% | 30.275% |
| iShares Core DAX® | 1,60 % | -7,45 % | 3,04 % | 46,26 % |
| iShares Nasdaq 100 | -0,73 % | -1,86 % | 15,42 % | 72,33 % |
| iShares Nikkei 225® | 1,30 % | -6,80 % | 34,31 % | 52,28 % |
| iShares S&P 500 | -0,39 % | -2,34 % | 9,91 % | 55,10 % |
Comments by tamam for this prediction
In the thread Collegium Pharmaceutical Inc diskutieren
Collegium in a huge potential market and solid operational momentum
Collegium continues to see a nice ramp-up in sales of Xtampza.
First-quarter revenues should be very strong as well, as regulatory action following the opioid crisis could make Xtampza a big winner.
(Vom Mitglied beendet)